REG - Assura plc - Appointment of CIO

AssuraAnnouncement

09/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI3011Da&default-theme=true

RNS Number : 3011D  Assura PLC  09 September 2024

9 September 2024

Assura plc

Appointment of CIO

Assura plc ("Assura" or the "Company"), the specialist healthcare property
investor and developer, has appointed Steven Noble to the newly created role
of Chief Investment Officer ("CIO") to support the business' short and
long-term growth strategy.

Steven joins the business effective immediately and will be responsible for
implementing Assura's investment strategy across all healthcare markets,
including delivery of capital recycling initiatives.

Steven was most recently Chief Investment Officer at Atrato Group, the
investment adviser to  Atrato Onsite Energy (ROOF) and Supermarket Income
REIT (SUPR), where he negotiated and executed over £2 billion of property
transactions and played an important role in taking SUPR from IPO to the
FTSE250. Prior roles include nine years at Lloyds in origination and risk
management with a focus on commercial real estate and KPMG where he qualified
as a chartered accountant.

Jonathan Murphy, Assura CEO, said: "Steven's appointment to the newly created
role of Chief Investment Officer is an important strategic step for Assura to
support our ambitious growth plans. The UK healthcare crisis continues to
worsen with an immense need for improved access to healthcare services across
the country. These factors are driving demand for infrastructure across an
increasingly diverse range of healthcare markets, to which Assura is best
placed to respond owning to our market position, sector expertise and
capabilities and our strong corporate culture. Steven's skills and expertise
will complement those already within the Executive Committee to deliver
against this demand and our long-term growth strategy."

Steven Noble, Assura CIO, said: "I'm delighted to be joining Assura at such an
exciting time, with the business strategically positioned to capture the
significant growth opportunities across broader healthcare markets. The
business' recent acquisition of 14 private hospitals and its JV with USS are a
clear indication of the group's ambition and I am incredibly excited to be
part of Assura's next stage of growth. I look forward to working as part of an
exceptionally skilled and experienced team at the UK's leading listed
healthcare property investor."

- Ends -

For more information, please contact:

 Assura plc                                  Tel: 0161 515 2043
 David Purcell, Investor Relations Director  Email: Investor@assura.co.uk

 FGS Global                                  Tel: 0207 251 3801

 Gordon Simpson                              Email: Assura@fgsglobal.com

 

Notes to Editors

Assura plc is the UK's leading specialist healthcare property investor and
developer. Assura enables better health outcomes through its portfolio of more
than 600 healthcare buildings, from which over six million patients are
served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the
EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7
billion and has a strong track record of growing financial returns and
dividends for shareholders.

At Assura we BUILD for health and as the first FTSE 250 certified B Corp we
are committed to keeping ESG at the heart of our strategy, creating Healthy
Environments (E) and Healthy Communities (S) and maintaining a Healthy
Business (G).

Further information is available at www.assuraplc.com
(http://www.assuraplc.com)

*EPRA is a registered trademark of the European Public Real Estate Association

Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUQGBUPCGAQ